Fig. 3: TRIM36 inhibits the MAPK/ERK phosphorylation pathway. | Cell Death & Disease

Fig. 3: TRIM36 inhibits the MAPK/ERK phosphorylation pathway.

From: TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways

Fig. 3

a, b TRIM36 significantly affected cellular growth in vivo. a Representative pictures of tumors. b Tumor volumes were measured at the indicated number of days after the mice were injected with tumor cells. Each bar represents the mean tumor volume ± the S.D. of five mice per group. *P < 0.05. c The knockdown of TRIM36 promoted changes in MAPK/ERK phosphorylation pathway marker expressions with gains in p-ERK, p-MSK1, C-MYC and Cyclin E1, and Cyclin D1 in the LNCAP line. d In contrast, the overexpression of METTL3 promoted changes with losses in p-ERK, p-MSK1, C-MYC and Cyclin E1, and Cyclin D1 in the PC-3 line. GAPDH was used as a loading control. *P < 0.05

Back to article page